Association of brain functional magnetic resonance activity with response to tumor necrosis factor inhibition in rheumatoid arthritis

Arthritis and Rheumatism

Volumn 65, Issue 2, 2013, Pages 325-333

  Rech, Juergen ^a   Hess, Andreas ^a   Finzel, Stephanie ^a   Kreitz, Silke ^a   Sergeeva, Marina ^a   Englbrecht, Matthias ^a   Doerfler, Arnd ^a   Saake, Marc ^a   Schett, Georg ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOLIZUMAB PEGOL; METHOTREXATE; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DEMOGRAPHY; DISEASE ACTIVITY; ELECTROENCEPHALOGRAM; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HAND; HUMAN; LIMBIC SYSTEM; MALE; PERCEPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; THALAMUS; TREATMENT RESPONSE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BRAIN; BRAIN MAPPING; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; JOINTS; MAGNETIC RESONANCE IMAGING; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873818745     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37761     Document Type: Article

References (33)

1. McInnes IB, Schett G,. Pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-19.
2. Firestein GS,. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61.
3. Feldmann M, Brennan FM, Maini RN,. Rheumatoid arthritis. Cell 1996; 85: 307-10.
4. Hess A, Axmann R, Rech J, Finzel S, Heindl C, Kreitz S, et al. Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A 2011; 108: 3731-6.
5. Cavanagh J, Paterson C, McLean J, Pimlott S, McDonald M, Patterson J, et al. Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: a clinical, proof-of-concept study. Ann Rheum Dis 2010; 69: 1251-2.
6. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
7. Tracey KJ,. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 2007; 117: 289-96.
8. Diamond B, Tracey KJ,. Mapping the immunological homunculus. Proc Natl Acad Sci U S A 2011; 108: 3461-2.
9. Smolen JS, Steiner G,. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003; 2: 473-88.
10. Conaghan PG,. Predicting outcomes in rheumatoid arthritis. Clin Rheumatol 2011; 30 Suppl 1: S41-7.
11. Smolen JS, Aletaha D, Grisar J, Redlich K, Steiner G, Wagner O,. The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now? Arthritis Res Ther 2008; 10: 208.
12. Factbox-World's top-selling drugs in 2014 vs 2010. URL: www.reuters.com/article/2010/04/13/roche-avastin-drugs-idUSLDE63C0BC20100413.
13. Ogawa S, Lee TM, Kay AR, Tank DW,. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci U S A 1990; 87: 9868-72.
14. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69: 1580-8.
15. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
16. Fries JF, Spitz PW, Kraines RG, Holman HR,. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
17. Knabl J, Witschi R, Hosl K, Reinold H, Zeilhofer UB, Ahmadi S, et al. Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature 2008; 451: 330-4.
18. Mai JK, Paxinos G, Voss T,. Atlas of the human brain. 3rd ed. Amsterdam: Elsevier Academic Press; 2008.
19. Conaghan P, Bird P, Ejbjerg B, O'Connor P, Peterfy C, McQueen F, et al. The EULAR-OMERACT rheumatoid arthritis MRI reference image atlas: the metacarpophalangeal joints. Ann Rheum Dis 2005; 64 Suppl 1: i11-21.
20. Wartolowska K, Hough MG, Jenkinson M, Andersson J, Wordsworth BP, Tracey I,. Structural changes of the brain in rheumatoid arthritis. Arthritis Rheum 2012; 64: 371-9.
21. Woolf CJ,. Evidence for a central component of post-injury pain hypersensitivity. Nature 1983; 306: 686-8.
22. Woolf CJ,. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011; 152 Suppl: S2-15.
23. Reinold H, Ahmadi S, Depner UB, Layh B, Heindl C, Hamza M, et al. Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin Invest 2005; 115: 673-9.
24. Lee YC, Nassikas NJ, Clauw DJ,. The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. Arthritis Res Ther 2011; 13: 211.
25. Lee YC, Chibnik LB, Lu B, Wasan AD, Edwards RR, Fossel AH, et al. The relationship between disease activity, sleep, psychiatric distress and pain sensitivity in rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2009; 11: R160.
26. Wendler J, Hummel T, Reissinger M, Manger B, Pauli E, Kalden JR, et al. Patients with rheumatoid arthritis adapt differently to repetitive painful stimuli compared to healthy controls. J Clin Neurosci 2001; 8: 272-7.
27. Morris VH, Cruwys SC, Kidd BL,. Characterisation of capsaicin-induced mechanical hyperalgesia as a marker for altered nociceptive processing in patients with rheumatoid arthritis. Pain 1997; 71: 179-86.
28. Jones AK, Derbyshire SW,. Reduced cortical responses to noxious heat in patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56: 601-7.
29. Schwienhardt P, Kalk N, Wartolowska K, Chessel I, Wordsworth P, Tracey I,. Investigation into the neural correlates of emotional augmentation of clinical pain. Neuroimage 2008; 40: 759-66.
30. Norheim KB, Harboe E, Goransson LG, Omdal R,. Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome-a double blind, randomised clinical trial. PLoS One 2012; 7: e30123.
31. Cavelti-Weder C, Furrer R, Keller C, Babians-Brunner A, Solinger AM, Gast H, et al. Inhibition of IL-1β improves fatigue in type 2 diabetes. Diabetes Care 2011; 34: e158.
32. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum 2004; 50: 1270-6.
33. Omdal R, Gunnarsson R,. The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis-a pilot study. Rheumatol Int 2005; 25: 481-4.